Male Fertility Guide: Semen Tests, Causes & Care Options

When to seek evaluation—and when not to wait

In a couple trying through regular unprotected intercourse, ASRM’s 2021 opinion recommends evaluation after 12 months when the female partner is under 35 and after six months when she is 35 or older. Over age 40, a more immediate evaluation may be warranted. Known conditions associated with infertility justify evaluation without waiting for those intervals. [2]

These are couple-level timing recommendations, not instructions to ignore a known male risk for a year. Prior gonadotoxic treatment, major testicular or reproductive problems, sexual difficulties preventing conception or previous abnormal results can change the urgency. People using donor gametes or other family-building routes also need an appropriate individualized pathway. [1] [2]

If cancer treatment or another potentially fertility-affecting treatment is planned, raise reproductive goals before treatment begins where feasible; do not delay urgent medical treatment on your own. Ask the responsible team about fertility-preservation counseling and how this fits the treatment timeline. [1]

Sudden severe testicular pain is an urgent medical problem, not a fertility appointment. Seek emergency assessment. A new lump, persistent pain or other concerning change also deserves clinical examination rather than a home sperm test. [6]

What to bring to the first consultation

• How long you have been trying, prior pregnancies and any pregnancy losses.
• Previous semen or hormone results, with dates and laboratory reports.
• Testicular history, infections, reproductive surgery, cancer treatment and relevant family history.
• All prescriptions, supplements, testosterone, anabolic steroids and recreational substances.
• Problems with erections, ejaculation or intercourse that affect the chance of conception.
• The other partner’s relevant evaluation and reproductive timeline, with consent.

This history directs testing. A complete examination can reveal information that a mail-in sample cannot, and some findings matter to general or genetic health as well as conception. Request a male reproductive specialist when appropriate instead of treating every abnormal result as a supplement deficiency. [1]

Semen analysis: useful measurements, not a pass/fail certificate

A semen analysis can describe volume, sperm concentration or number, movement and shape, among other findings. The measures have biological variability and may change between samples. AUA/ASRM notes that considering at least two analyses about a month apart is particularly important when the first has abnormal parameters. [1]

Follow the laboratory’s collection instructions and report an incomplete sample or a problem with collection or transport. Do not hide these details because they feel embarrassing; they can change interpretation. Ask whether a repeat is needed under suitable conditions rather than assuming the first number is permanent. [1]

A result within a reference range is not a guarantee of conception; a value outside it is not the same as zero chance. Ask the specialist to explain which findings are important and how they change the plan. [1]

Hormones, genetics, imaging and DNA fragmentation

Further testing should follow the clinical question. Hormone assessment may be indicated with low desire, erectile dysfunction, low or absent sperm counts or other findings. Genetic testing is important in selected presentations, not a routine consumer panel for everyone who has not conceived. [1]

AUA/ASRM advises against sperm DNA fragmentation testing as part of the routine initial evaluation of an infertile couple. It identifies different roles in circumstances such as recurrent pregnancy loss and selected later evaluations. “Not routine initially” is not the same as “never useful,” and a single high score does not establish which treatment will lead to a baby. [1]

Routine pelvic imaging is also not an automatic first step. Imaging can be appropriate for a specific suspected obstruction or other clinical finding. Ask what the proposed test would change, including whether an apparently abnormal result has a validated treatment pathway. [1]

Genetic results may have implications for a partner or future child. Ask about counseling before and after testing rather than interpreting a laboratory report through an online forum. The guideline grades some recommendations as expert opinion or lower-certainty evidence; these should not be marketed as universally proven procedures. [1]

Testosterone can work against a fertility goal

Exogenous testosterone can suppress the signals needed for sperm production. AUA/ASRM advises clinicians not to prescribe it for males interested in current or future fertility. Increased desire or a higher blood testosterone value does not mean sperm production has improved. [1]

Disclose any prescribed testosterone, bodybuilding hormones or previous steroid use. Do not independently add fertility drugs or an online “post-cycle” regimen. The appropriate plan depends on the cause, duration of exposure and reproductive timeline, and recovery should not be assumed to be immediate or guaranteed. [1]

See the low testosterone guide for the separate diagnosis and TRT safety discussion. If a clinic proposes testosterone while you are trying for pregnancy, make sure the fertility implications have been explicitly addressed.

Treatment choices depend on the cause and timeline

AUA/ASRM recommends considering repair for a clinical, palpable varicocele in men attempting conception with infertility and abnormal semen parameters, with an exception for azoospermic men in that recommendation. It recommends against repair of a nonpalpable varicocele found only on imaging. Do not translate “varicocele detected” into an automatic operation. [1]

IUI, IVF and ICSI are not interchangeable. ICSI places a sperm into an egg within an IVF process, but obtaining fertilization is not the same outcome as a live birth. Ask for results relevant to your situation, including the other partner’s age and factors, rather than a clinic-wide headline success rate. [1]

Discuss burden, time, cost, recovery, uncertainties and alternatives. A procedure that improves a semen measurement may still not fit the couple’s timeline. Some people choose donor sperm or other routes to family building; a good consultation should make room for preferences as well as laboratory values. [1]

Antioxidants: do not confuse a plausible mechanism with a baby

AUA/ASRM states that supplements such as antioxidants and vitamins have questionable clinical utility for male infertility and that data are inadequate to recommend specific agents. This is a narrower, more useful conclusion than either “all antioxidants work” or “nutrition never matters.” [1]

The MOXI trial tested an antioxidant combination against placebo in men with male-factor infertility. It did not demonstrate improvement in the semen or DNA-integrity measures that justified expansion of the trial. Reported live birth was 15% versus 24% at six months, a nonsignificant difference (P=0.14). The study was limited in size and not adequately powered to settle the live-birth question; the lower numerical rate should not be presented as proof of harm. [3]

The open-access report identifies NIH/NICHD funding. We inspected selected methods, results, discussion and funding sections, not every supplement or ingredient trial. Its result does not establish that all possible formulations have identical effects, but it does challenge a routine promise that an antioxidant mixture improves fertility. [3]

A larger trial of folic acid and zinc

FAZST randomized 2,370 men from couples seeking infertility treatment. Live birth occurred in 34% of the folic-acid/zinc group and 35% of placebo recipients; the reported risk difference was −0.9 percentage points (95% confidence interval −4.7 to 2.8). Most semen parameters were not significantly improved. [4]

The trial also reported higher sperm DNA fragmentation in the supplement group, and NICHD’s summary describes more gastrointestinal symptoms. Live-birth information was available for all couples, but semen was available for 69% of men at six months, a limitation when interpreting that outcome. Our paper-level review was of the abstract, supplemented by the NICHD summary—not the complete article and supplements. [4] [5]

The practical message is not to use a trial regimen as a shopping list. Correcting an identified nutritional deficiency is a different clinical question from giving high-dose supplements to every man seeking pregnancy. The men’s supplements guide covers how to judge those claims.

Daily steps and a useful review plan

Review smoking, alcohol and substance use, occupational exposures, sleep, medicines and general health with the clinician. The strength of fertility-specific lifestyle evidence varies; do not accept a claim that one food, underwear style or “detox” guarantees conception. General health support can be worthwhile without a promised fertility percentage. [1]

• Name the finding being treated and the outcome that matters.
• Agree when semen or other tests should be repeated and why.
• Set a time to reconsider the plan in light of both partners’ circumstances.
• Ask whether a recommendation is supported by strong trials, limited evidence or expert opinion.
• Seek emotional support if testing or treatment is putting strain on either partner.

Use the men’s health overview for related sexual, hormonal and mental-health pathways. A fertility plan should have an accountable clinician and an agreed next decision—not an indefinite series of supplement purchases.

A fertility appointment record

This original organizer is not a fertility score or a prediction of pregnancy.

How this guide was researched

Editorial update: October 19, 2026. Key guideline, public-health and safety statements were rechecked against the linked sources during this update. This remains an AI-assisted educational synthesis with no independent medical review; it is not an exhaustive literature search or individualized care.

AI-assisted editorial synthesis, not independent clinical review or a systematic review. We inspected relevant AUA/ASRM 2024 recommendations, ASRM evaluation timing and selected open-access MOXI sections. FAZST was checked through its abstract and the NICHD summary, not the full report. Semen outcomes, pregnancy and live birth are kept separate, and trial formulations are not reproduced as a self-treatment protocol.

Sources checked October 18, 2026. Medical information can change. This is general education, not diagnosis or individualized treatment. For urgent symptoms use local emergency or urgent-care services.

Sources and evidence notes

1. AUA/ASRM: Diagnosis and Treatment of Infertility in Men, amended 2024. Selected reproductive-history, semen, genetic, imaging, varicocele, testosterone and supplement recommendations inspected.
2. ASRM: Fertility evaluation—committee opinion (2021). Timing statements inspected; the female partner’s age and known risks influence couple-level evaluation.
3. Steiner et al.: MOXI randomized trial (2020). Selected open-access methods, results, discussion and funding sections inspected. Randomized groups reported as 85 and 86; the article also contains a different enrollment total in its abstract, so no single combined enrollment total is asserted here.
4. Schisterman et al.: Folic Acid and Zinc Supplementation Trial (2020). PubMed abstract inspected, not the complete paper or supplements. DOI: 10.1001/jama.2019.18714.
5. NICHD: Folic Acid and Zinc Supplementation Trial. Agency study description and results summary inspected.
6. NHS: Testicle pain. Patient urgent-care guidance; use local emergency services outside the UK.